The global community acquired bacterial pneumonia (CABP) treatment market is poised for significant growth over the next decade, according to a recent market analysis. With increasing awareness about the disease and advancements in technology driving diagnosis and treatment options, the market is anticipated to reach a valuation of US$ 8.38 billion by 2033, exhibiting a …